First report of durability of antibody response in maintenance haemodialysis patients and kidney transplant recipients vaccinated with ChAdOx1 nCoV-19 vaccine: A prospective, multicentre, observational, study

ABSTRACT

Introduction: Immunogenicity of COVID-19 vaccines in maintenance haemodialysis (MHD) and kidney transplant recipients (KTR) are suboptimal. However, there is no data in the context of durability of humoral response with ChAdOx1 nCoV-19 vaccines in these groups. Method(s) This was a multicentre, prospective cohort study of MHD (n = 73), KTR (n = 62) and control (n = 22) who received ChAdOx1 nCoV-19 vaccine between Feb 2021 to April 2022. Vaccine response was measured at 1m and 6 m after the second dose. Result(s) The antibody response in MHD group compared to control group was statistically lower at both 1-m and 6 m. However only six (8.2%) cases showed negative seroresponse at 1-m, and five (6.84%) had negative response at 6-m. For KTR group, overall, 26(35.61%) cases had no seroresponse and 36(64.39%) seroconverted at 6 months. In this group, there was lower antibody levels at 6-m, however there was no statistically difference compared to 1 m. In comparing MHD group and KTR, the antibody levels were significantly lower in KTR group. The risk factors for no response at 6-m in KTR group was older age, history of anti-rejection in recent times and early transplant period while only age was linked with low response in MHD group. [Formula presented] Conclusion(s) Our report highlights the consistent and durable response of COVID-19 vaccine in both group of patients, despite having an attenuated response compared to control. No conflict of interestCopyright © 2023